ReviewJournal of translational medicine2026
Cancer-associated fibroblasts: enablers of tumor drug resistance.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanomaterials targeting cancer-associated fibroblasts to overcome stromal barriers in cancer immunotherapy.Journal of nanobiotechnology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTreatment failure due to drug resistance has always been a “roadblock” to cancer cure. For a long time, drug resistance research has focused on the nature of the cancer cells themselves; however, more and more studies have found the non-negligible significance of the tumor microenvironment (TME) in cancer malignant progression and therapeutic resistance. Within the TME, cancer-associated fibroblasts (CAFs) represent the most prevalent and highly plastic cells, exerting profound influence on tumor progression.
methodsWe integrate recent literature and synthesize evidence from both preclinical and clinical studies to elucidate the potential mechanisms by which CAFs contribute to therapeutic resistance and to summarize up-to-date research developments in nanotherapeutic strategies targeting CAFs.
resultsEmerging findings demonstrate that CAFs substantially contribute to drug resistance by secreting various soluble factors and metabolites, remodeling the extracellular matrix (ECM), and regulating immune responses and cell death. Nanotherapeutic strategies show considerable promise in improving treatment efficacy, while further research is required to facilitate their clinical translation.
conclusionsCAFs act as key orchestrators of the drug-resistant TME, positioning them as compelling targets for next-generation anticancer strategies. Moreover, advancing progress in nano-strategies targeting CAFs holds substantial promise for improving clinical outcomes in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.